Protein binder toolbox for studies of solute carrier transporters.

High-affinity protein binders Protein binder validation SLC12A6 Solute carriers Transmembrane transporters

Journal

Journal of molecular biology
ISSN: 1089-8638
Titre abrégé: J Mol Biol
Pays: Netherlands
ID NLM: 2985088R

Informations de publication

Date de publication:
13 Jun 2024
Historique:
received: 05 03 2024
revised: 07 06 2024
accepted: 10 06 2024
medline: 16 6 2024
pubmed: 16 6 2024
entrez: 15 6 2024
Statut: aheadofprint

Résumé

Transporters of the solute carrier superfamily (SLCs) are responsible for the transmembrane traffic of the majority of chemical substances in cells and tissues and are therefore of fundamental biological importance. As is often the case with membrane proteins that can be heavily glycosylated, a lack of reliable high-affinity binders hinders their functional analysis. Purifying and reconstituting transmembrane proteins in their lipidic environments remains challenging and standard approaches to generate binders for multi-transmembrane proteins, such as SLCs, channels or G protein-coupled receptors (GPCRs) are lacking. While generating protein binders to 27 SLCs, we produced full length protein or cell lines as input material for binder generation by selected binder generation platforms. As a result, we obtained 525 binders for 22 SLCs. We validated the binders with a cell-based validation workflow using immunofluorescent and immunoprecipitation methods to process all obtained binders. Finally, we demonstrated the potential applications of the binders that passed our validation pipeline in structural, biochemical, and biological applications using the exemplary protein SLC12A6, an ion transporter relevant in human disease. With this work, we were able to generate easily renewable and highly specific binders against SLCs, which will greatly facilitate the study of this neglected protein family. We hope that the process will serve as blueprint for the generation of binders against the entire superfamily of SLC transporters.

Identifiants

pubmed: 38878854
pii: S0022-2836(24)00260-2
doi: 10.1016/j.jmb.2024.168665
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

168665

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: L.S., L.A. and S.T. are employees of Axxam S.p.A. Y.-N.C. and V.P. are employees of Nuvisan GmbH. G.S.-F. is scientific founder and shareholder of Proxygen and Solgate. The rest of authors declare no competing interests.

Auteurs

Zuzana Gelová (Z)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Alvaro Ingles-Prieto (A)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Tina Bohstedt (T)

Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Fabian Frommelt (F)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Gamma Chi (G)

Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Yung-Ning Chang (YN)

Nuvisan ICB GmbH, Berlin, Germany.

Julio Garcia (J)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Gernot Wolf (G)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Lucia Azzollini (L)

Axxam SpA, Bresso (Milano), Italy.

Sara Tremolada (S)

Axxam SpA, Bresso (Milano), Italy.

Andreea Scacioc (A)

Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Jesper S Hansen (JS)

Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Iciar Serrano (I)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Aida Droce (A)

Department of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark.

Jenifer Cuesta Bernal (J)

Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany.

Nicola A Burgess-Brown (NA)

Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Elisabeth P Carpenter (EP)

Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Katharina L Dürr (KL)

Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Peter Kristensen (P)

Department of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark.

Eric R Geertsma (ER)

Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany.

Saša Štefanić (S)

Nanobody Service Facility, University of Zurich, AgroVet-Strickhof, Eschikon, Switzerland.

Lia Scarabottolo (L)

Axxam SpA, Bresso (Milano), Italy.

Tabea Wiedmer (T)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Vera Puetter (V)

Nuvisan ICB GmbH, Berlin, Germany.

David B Sauer (DB)

Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Giulio Superti-Furga (G)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria. Electronic address: gsuperti@cemm.oeaw.ac.at.

Classifications MeSH